• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Hypertens Res . COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19

tetano

Editor, Senior Moderator
Hypertens Res


. 2022 Dec 23.
doi: 10.1038/s41440-022-01134-5. Online ahead of print.
COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19


Shigeru Shibata[SUP] 1 [/SUP], Kazuo Kobayashi[SUP] 2 3 [/SUP], Masami Tanaka[SUP] 4 [/SUP], Kei Asayama[SUP] 5 [/SUP], Eiichiro Yamamoto[SUP] 6 [/SUP], Hironori Nakagami[SUP] 7 8 [/SUP], Satoshi Hoshide[SUP] 9 [/SUP], Takuya Kishi[SUP] 10 [/SUP], Chisa Matsumoto[SUP] 11 [/SUP], Masaki Mogi[SUP] 12 [/SUP], Satoshi Morimoto[SUP] 13 [/SUP], Koichi Yamamoto[SUP] 14 [/SUP], Masashi Mukoyama[SUP] 15 [/SUP], Kazuomi Kario[SUP] 9 [/SUP], Koichi Node[SUP] 16 [/SUP], Hiromi Rakugi[SUP] 14 [/SUP]



Affiliations

Abstract

The number of reported cases with coronavirus disease 2019 (COVID-19) has exceeded 620 million worldwide, still having a profound impact on people's health and daily lives since its occurrence and outbreak in December 2019. From the early phase of the COVID-19 pandemic, there has been a concern that the rapid spread of this communicable disease can negatively influence non-communicable diseases. Accumulating data indicate that the restriction on the access to medical care, psychological distress, and life-style changes triggered by the pandemic have indeed affected blood pressure control in hypertensive patients. Since our previous report in 2020 that summarized the findings of the literature related to COVID-19 and hypertension, there has been a considerable progress in our understanding of the association between these two disorders; nonetheless, there are remaining challenges and emerging questions in the field. In this article, we aim to summarize the latest information on the impact of the pandemic on blood pressure control, the use of the renin-angiotensin system inhibitors in patients with COVID-19, and the blood pressure changes as one of the possible post-acute sequelae of COVID-19 (also known as long COVID). We also summarize the evidence of telemedicine and COVID-19 vaccination in hypertensive subjects, based on data available as of June 2022.

Keywords: High blood pressure; Long COVID; NCD; RAS inhibitors; SARS-CoV-2.
 
Back
Top Bottom